ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,234, issued on Sept. 8, was assigned to Voyager Therapeutics Inc. (Lexington, Mass.). "Tau binding compounds" was invented by Vinodhbabu Ku... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,235, issued on Sept. 8, was assigned to Zoetis Services LLC (Parsippany, N.J.). "Caninized anti-TGFBeta antibodies" was invented by Lisa Ma... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,236, issued on Sept. 8, was assigned to VALITOR INC. (Berkeley, Calif.). "Hydrophilic linkers for antibody or DARPin conjugates" was invent... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,237, issued on Sept. 8, was assigned to Flow Pharma Inc. (Redwood City, Calif.). "Controlled release of antibodies to modulate cytokines" w... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,239, issued on Sept. 8, was assigned to MERCK PATENT GMBH (Darmstadt, Germany). "Anti-CEACAM5 antibodies and conjugates and uses thereof" w... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,240, issued on Sept. 8, was assigned to ImmunEdge Inc. (Redwood City, Calif.) and The Board of Trustees of the Leland Stanford Junior Univer... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,241, issued on Sept. 8, was assigned to Gilead Sciences Inc. (Foster City, Calif.). "Antibodies that bind to human chemokine (C-C motif) re... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,243, issued on Sept. 8, was assigned to Hoffmann-La Roche Inc. (Little Falls, N.J.). "Dosing for treatment with anti-CD20/anti-CD3 bispecif... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,245, issued on Sept. 8, was assigned to The Board of Trustees of the Leland Stanford Junior University (Stanford, Calif.). "Compositions an... Read More
ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,246, issued on Sept. 8, was assigned to Memorial Sloan Kettering Cancer Center (New York). "Anti-GPA33 multi-specific antibodies and uses t... Read More